Sachi Ahmed is a senior scientist at Merck & Co. working on ADCs and bispecifics.
With a background in chemical engineering, she has been a researcher in the field of cancer for 20 years and is a published author in scientific journals, including a publication in Nature magazine on nasal delivery of an IgM drug for SARS-CoV-2 variants. Sachi is also a key inventor on a US patent for glyco-engineered IgMs.
Prior to Merck, she was at IGM biosciences for 7 years where she led the research antibody production team focused on novel approaches in cancer and Covid-19 therapeutics. She has also previously worked for biotechnology companies such as Abbott, Abbvie, and Merck and has expertise in in-vitro glycoengineering and antibody production to support the development of innovative biologics.
Sachi was a founder of the PTPS (Peers Teaching Peers Science) program at the FAME Charter School in Fremont, CA, aimed to inspire children to gain confidence and interest in science and engineering. She is also an advocate for women's empowerment, and founded the Women of IGM group. She is actively involved in Women in Bio and the Chan Zuckerberg Initiative.
She is regularly invited to speak at various scientific conferences. She was an invited speaker at the Silicon Valley Women in Engineering conference.
Sachi obtained her Bachelor of Applied Science in Chemical Engineering from the University of Toronto, with a specialization in Biomedical Engineering, later studying and pursuing a career in Biochemistry and Biomedical Sciences.
Sachi Ahmed is featured on the company’s homepage at https://igmbio.com/.
Comments
Post a Comment